

Mikashmi Kohli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5937976/publications.pdf>

Version: 2024-02-01

19
papers

1,209
citations

623734

14
h-index

794594

19
g-index

19
all docs

19
docs citations

19
times ranked

1051
citing authors

#	ARTICLE	IF	CITATIONS
1	GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy. <i>Journal of Clinical Epidemiology</i> , 2020, 122, 129-141.	5.0	168
2	GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. <i>Journal of Clinical Epidemiology</i> , 2020, 122, 142-152.	5.0	167
3	Xpert [®] MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. <i>The Cochrane Library</i> , 2018, 8, CD012768.	2.8	153
4	The Lancet Commission on diagnostics: transforming access to diagnostics. <i>Lancet</i> , The, 2021, 398, 1997-2050.	13.7	149
5	Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. <i>The Cochrane Library</i> , 2019, 6, CD009593.	2.8	144
6	Advances in Molecular Diagnosis of Tuberculosis. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	83
7	Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults. <i>The Cochrane Library</i> , 2021, 2021, CD012768.	2.8	63
8	Extrapulmonary tuberculosis. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 931-948.	2.5	60
9	Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. <i>The Cochrane Library</i> , 2021, 2021, CD009593.	2.8	58
10	Adoption and uptake of the lateral flow urine LAM test in countries with high tuberculosis and HIV/AIDS burden: current landscape and barriers. <i>Gates Open Research</i> , 2020, 4, 24.	1.1	33
11	Biomarkers That Correlate with Active Pulmonary Tuberculosis Treatment Response: a Systematic Review and Meta-analysis. <i>Journal of Clinical Microbiology</i> , 2022, 60, JCM0185921.	3.9	28
12	Adoption and uptake of the lateral flow urine LAM test in countries with high tuberculosis and HIV/AIDS burden: current landscape and barriers. <i>Gates Open Research</i> , 2020, 4, 24.	1.1	25
13	Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms. <i>The Cochrane Library</i> , 2021, 2021, CD013694.	2.8	19
14	Availability of essential diagnostics in primary care in India. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1064-1065.	9.1	17
15	Diagnostic accuracy of centralised assays for TB detection and detection of resistance to rifampicin and isoniazid: a systematic review and meta-analysis. <i>European Respiratory Journal</i> , 2021, 57, 2000747.	6.7	16
16	SARS-CoV-2 testing in low- and middle-income countries: availability and affordability in the private health sector. <i>Microbes and Infection</i> , 2020, 22, 511-514.	1.9	10
17	Most common reasons for primary care visits in low- and middle-income countries: A systematic review. <i>PLOS Global Public Health</i> , 2022, 2, e0000196.	1.6	9
18	Urinary EPCR and dermcidin as potential novel biomarkers for severe adult OSA patients. <i>Sleep Medicine</i> , 2019, 64, 92-100.	1.6	4

#	ARTICLE	IF	CITATIONS
19	Xpert MTB/RIF and Xpert Ultra assays for pulmonary tuberculosis and rifampicin resistance in adults irrespective of signs or symptoms of pulmonary tuberculosis. The Cochrane Library, 2020, , .	2.8	3